SR-TWAS: Leveraging Multiple Reference Panels to Improve TWAS Power by Ensemble Machine Learning

Randy L. Parrish[1,2], Aron S. Buchman[3], Shinya Tasaki[3], Yanling Wang[3], Denis Avey[3], Jishu Xu[3], Philip L. De Jager[4], David A. Bennett[3], Michael P. Epstein[1], Jingjing Yang[1*]

1. Center for Computational and Quantitative Genetics, Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, 30322, USA
2. Department of Biostatistics, Emory University School of Public Health, Atlanta, GA 30322, USA
3. Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, 60612, USA
4. Center for Translational and Computational Neuroimmunology, Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY10032, USA

[*] Correspondence Author: jingjing.yang@emory.edu

Abstract

Multiple reference panels of a given tissue or multiple tissues often exist, and multiple regression methods could be used for training gene expression imputation models for TWAS. To leverage expression imputation models (i.e., base models) trained with multiple reference panels, regression methods, and tissues, we develop a Stacked Regression based TWAS (SR-TWAS) tool which can obtain optimal linear combinations of base models for a given validation transcriptomic dataset. Both simulation and real studies showed that SR-TWAS improved power, due to increased effective training sample sizes and borrowed strength across multiple regression methods and tissues. Leveraging base models across multiple reference panels, tissues, and regression methods, our real application studies identified 6 independent significant risk genes for Alzheimer's disease (AD) dementia for supplementary motor area tissue and 9 independent significant risk genes for Parkinson's disease (PD) for substantia nigra tissue. Relevant biological interpretations were found for these significant risk genes.

Introduction

Two-stage transcriptome-wide association studies (TWAS) have been widely used in genetic studies of complex traits due to the convenience of using publicly-available transcriptomic reference panels and summary-level genome-wide association study (GWAS) datasets[1–5]. The standard two-stage TWAS method[6,7] first trains gene expression imputation models (per gene per tissue) using a transcriptomic reference panel in Stage I, taking quantitative gene expression traits as response variables and nearby (cis-) or genome-wide (cis- and trans-) genetic variants as predictors. The non-zero genetic effect sizes estimated in the gene expression imputation models are considered effect sizes of a broad sense of expression quantitative trait loci (eQTL), which are taken as variant weights to conduct gene-based association tests with GWAS data (individual-level or summary-level) in Stage II.

Various TWAS techniques have been developed, employing diverse regression methods to train models for imputing gene expression. Additionally, multiple transcriptomic reference panels are made available to the public and could be used in TWAS. Consequently, it is possible to train multiple gene expression imputation models by employing distinct regression methods, employing multiple transcriptomic reference panels of the same tissue type, or utilizing transcriptomic data from multiple tissues within a given reference panel. For example, multiple regression methods, such as penalized regression with Elastic-Net penalty (used by PrediXcan[7,8]) and nonparametric Bayesian Dirichlet process regression (DPR) model (used by TIGAR[9]), have trained gene expression imputation models using the same Genotype-Tissue Expression (GTEx)[10] V8 reference data of 48 human tissue types. The Religious Orders Study (ROS)[11], Rush Memory and Aging Project (MAP)[11], and the GTEx[10] V8 project all profile transcriptomic data of prefrontal cortex (PFC) brain tissue and genome-wide genetic data of the same samples,

providing multiple reference panels of PFC tissue for TWAS. Thus, leveraging multiple trained

gene expression imputation models of the same target gene across multiple regression methods,

multiple reference panels, and multiple tissue types is expected to improve TWAS power, for

more robustly modeling the unknown genetic architecture of the target gene expression by

multiple regression models, having an increased training sample size with multiple reference

panels, or borrowing strength across multiple tissue types with correlated gene expression.

Multiple approaches that can take advantage of transcriptomic reference data for multiple tissues

and/or multiple reference panels have been developed. For example, UTMOST uses group

LASSO-penalized multivariate regression to impute cross-tissue expression[12]. SWAM estimates

a vector of weights for input expression imputation models such that the weighted average of the

input models will give the lowest mean squared error with respect to individual-level reference

expression of the target tissue[13]. However, these approaches have drawbacks such as requiring

individual-level reference data, being computationally expensive, and user-unfriendly. For

example, UTMOST requires individual-level reference data for all tissues to train gene

expression imputation models. In order to control for multicollinearity, SWAM considers a

regularization parameter which requires fine-tuning based on the covariance structure of

Genetically Regulated gene eXpression (GReX) of all considered tissues which must be derived

using individual-level reference transcriptomic data[13]. Additionally, SWAM requires that the

input of trained gene expression imputation models in the same SQL database format as used for

PrediXcan output[13].

To fill this gap, we develop a novel TWAS method to leverage multiple summary-level gene

expression imputation models (i.e., base models) trained for the same target gene by the

ensemble machine learning technique of stacked regression[14,15]. We refer to this novel TWAS

method as Stacked Regression-based TWAS (i.e., SR-TWAS). SR-TWAS first uses a validation

transcriptomic dataset of the target tissue type to optimally train a set of weights for the multiple

expression imputation base models per target gene (Stage I), by optimizing the gene expression

prediction R^2 (i.e., the squared correlation between observed and predicted gene expression

levels) in the validation dataset. Then SR-TWAS takes the weighted average eQTL effect sizes

as the corresponding variant weights for gene-based association tests in Stage II. The trained

expression imputation models by SR-TWAS are specific for the tissue type of the validation

data, and the identified TWAS risk genes are interpreted with potential genetic effects mediated

through their gene expression of the validation tissue type.

In the following sections, we first briefly describe the stacked regression method used by SR-

TWAS and the GTEx V8 and ROS/MAP reference transcriptomic datasets used in this study.

Then we describe the results of our simulation studies, validation studies using the real reference

data, as well as application TWAS of AD dementia and PD. Last, we end with a discussion.

Results

Overview of SR-TWAS

In the framework of TWAS[7,9,16], a multiple linear regression model is assumed for training gene

expression imputation models, taking quantitative gene expression levels $\boldsymbol{E_g}$ of the target gene

and tissue as the response variable and cis-acting genetic variants nearby the target gene region

(genotype matrix $\boldsymbol{G}$) as predictors, as shown in the following formula:

$$\boldsymbol{E_g} = \boldsymbol{Gw} + \boldsymbol{\epsilon}, \qquad \boldsymbol{\epsilon} \sim N(\boldsymbol{0}, \boldsymbol{I}).$$

The eQTL effect sizes w could be trained by different regression methods and/or using different

reference panels with matched expression and genotype data (E_g, G).

Assume there are a total of K base gene expression imputation models trained for the same target

gene, with $\widehat{w_k}, k = 1, \dots, K$. Let $\mathbf{E}_{vg}$ denote the gene expression levels of the target gene g for

the target tissue type in the validation data, and $\mathbf{G}_v$ denote the genotype matrix of genetic

predictors in the validation data. Then the predicted GReX of the validation samples by the kth

base model are given by $\mathbf{G}_v \widehat{\mathbf{w}}_k$. The stacked regression method[14,15] will solve for a set of optimal

base model weights $\zeta_1, \dots, \zeta_K$, by maximizing the regression R^2 between the profiled gene

expression $\mathbf{E}_{vg}$ and the weighted average GReX, $\sum_{k=1}^{K} \zeta_k \mathbf{G}_v \widehat{\mathbf{w}}_k$, of K base models, i.e.,

minimizing the following loss function of $1 - R^2$:

106
$$\text{minimize}_{(\zeta_k; k=1,\dots,K)} \frac{\left\| \mathbf{E}_{vg} - \sum_{k=1}^{K} \zeta_k \mathbf{G}_v \widehat{\mathbf{w}}_k \right\|^2}{\left\| \mathbf{E}_{vg} - \bar{E}_{vg} \right\|^2}, \qquad \text{s.t.} \sum_{k=1}^{K} \zeta_k = 1, \quad \zeta_k \in [0,1].$$

As a result, we will obtain a set of model weights ζ_k for $k = 1, \dots, K$ base models, and a set of

eQTL effect sizes $\widetilde{\mathbf{w}}$ given by the weighted average of the eQTL effect sizes of K base models,

$\widetilde{\mathbf{w}} = \sum_{k=1}^{K} \zeta_k \widehat{\mathbf{w}}_k$ (Stage I). Then the final predicted GReX for test genotype data $\mathbf{G}_t$ is given by

$\widehat{\mathrm{GReX}}_g = \mathbf{G}_t \widetilde{\mathbf{w}}$, and $\widetilde{\mathbf{w}}$ will be taken as variant weights in the gene-based association tests by

SR-TWAS in Stage II. Genes with 5-fold cross validation (CV) $R^2 > 0.5\%$ in the validation

dataset by SR-TWAS are considered as having a valid imputation model and will be tested in

Stage II[9]. Here, $\widetilde{\mathbf{w}}$ is the trained eQTL effect sizes by SR-TWAS (Stage I) for the target gene of

the tissue of the validation data and identified significant genes from Stage II have potential

genetic effects mediated through the transcriptome of the tissue of the validation data.

Reference Transcriptomic Data

GTEx V8. The Genotype-Tissue Expression project version 8 (GTEx V8) release provides a

comprehensive reference dataset of Whole Genome Sequencing (WGS) genotype data with

matched RNA-seq transcriptomic data from 54 non-diseased tissues of 838 post-mortem donors

of European ancestry[10]. For our real data analysis, we used publicly-available GReX imputation

models trained by TIGAR-V2[9] and PrediXcan[7,8,17] with GTEx V8 reference data for European

subjects as base models. Supplementary Table 1 shows the disease status of GTEx subjects for

tissues used in the AD or PD TWAS. AD or other dementia was reported for only 4% of

subjects, with missing data for ~1% subjects. The majority of GTEx subjects used in PD TWAS

were reported to be without PD, with <1% reported with PD and with missing data for 13% of

training and 6% of validation subjects.

ROS/MAP. The Religious Orders Study (ROS) and Rush Memory and Aging Project (MAP) are

two longitudinal clinical-pathologic cohort studies of aging and AD, which are collectively

referred to as ROS/MAP[11]. ROS recruits participants from religious orders across the U.S. while

MAP recruits lay persons in the northeastern Illinois area[11]. All participants in both studies are

without known dementia and agree to annual clinical evaluations and brain donation upon

death[11]. Only subjects of European ancestry were used in this study. Disease status of ROS/MAP

participants are shown in Supplementary Table 1. Of the ROS/MAP subjects used in the training

data of AD TWAS, 57% had normal cognitive function, 40% had AD or other dementia, and 4%

had missing disease status. Of the ROS/MAP subjects used in the validation data of AD TWAS,

75% had normal cognitive function and 25% had AD or other types of dementia.

Simulation Studies

 Simulation study design

We used the real genotype data of gene *ABCA7* from ROS/MAP and GTEx V8 to simulate gene

expression and phenotypes, and considered multiple scenarios with varying proportions of causal

SNPs ($p_{causal} = (0.001, 0.01, 0.05, 0.1)$) and gene expression heritability (i.e., the proportion of

gene expression variation due to genetics, $h_e^2 = (0.1, 0.2, 0.5)$). We randomly selected n=465

training samples with Whole Genome Sequencing (WGS) genotype data from the ROS/MAP

cohort and GTEx V8 cohort, respectively. We randomly selected n=400 and n=800 samples with

WGS genotype data from ROS/MAP as our validation and test cohorts, respectively. ROS/MAP

training, validation, and test samples were simulated with the same causal SNPs (i.e., eQTL),

while training samples from the GTEx V8 cohort were simulated with true causal SNPs that

were 50% overlapped with the ones for ROS/MAP samples. The simulated expression

heritability was the same for both ROS/MAP and GTEx V8 samples.

We compared the performance of SR-TWAS with a Naïve approach which takes the average of

base models as the trained gene expression imputation model, that is, taking $\zeta_k = \frac{1}{K}, k =$

$1, \dots, K$. Two base models per gene were respectively trained by PrediXcan (penalized

regression with Elastic-Net penalty; PrediXcan-GTEx) with the GTEx training samples (n=465),

and by TIGAR (nonparametric Bayesian Dirichlet process regression; TIGAR-ROSMAP) with

the ROS/MAP training samples (n=465). SR-TWAS and Naïve models were then obtained by

using these trained base models. Validation data ($n = 400$) were used to train SR-TWAS models

and an additional TIGAR base model (TIGAR_ROSMAP_valid). The SR-TWAS and

TIGAR_ROSMAP_valid models were then averaged to create a new model (Avg-valid+SR).

Gene expression imputation models (by SR-TWAS and Naïve methods) with 5-fold cross-

validation $R^2 > 0.5\%$ in the validation cohort were considered valid models, which were used to

produce the Avg-valid-SR models and used in the follow-up gene-based association tests. Test

data (n=800) were used for assessing GReX prediction performance and TWAS power, with

1,000 repeated simulations per scenario. We compared the performance of three base models of

the training and validation data (PrediXcan-GTEx, TIGAR-ROSMAP, and TIGAR-

ROSMAP_valid), Naïve method, SR-TWAS, and Avg-valid+SR models.

Simulation study results

As shown in **Fig. 1**, we showed that Avg-valid+SR obtained the highest test R^2 for gene

expression imputation across 11 of 12 scenarios, and the SR-TWAS models had the second-best

performance. SR-TWAS obtained the highest test R^2 for gene expression imputation in the

$p_{\text{causal}} = 0.01$ and $h_e^2 = 0.5$ scenario, where it slightly outperformed the averaged models. The

base models trained by TIGAR with ROS/MAP training and validation samples (TIGAR-

ROSMAP, TIGAR-ROSMAP_valid) performed similarly well, because the test data were

generated under the same model assumptions as the ROS/MAP training and validation data.

Here, the Avg-valid+SR models performed best for leveraging the predictive information

provided by all three base models. The Naïve method and PrediXcan-GTEx base models did not

perform well because the PrediXcan-GTEx base models were trained using GTEx training data

which only shared half of the true causal SNPs as the validation and test data. The Naïve

approach of taking averages of the PrediXcan-GTEx and TIGAR-ROSMAP base models had

poor performance because of the heterogeneous genetic architecture between the GTEx training

cohort and test cohort.

As expected, model performance improved with increasing true expression heritability h_e^2 with

the same training sample size. For all considered scenarios, the highest test R^2 were obtained

under a sparse causality model with $p_{\text{causal}} = 0.001$, where true causal SNP effect sizes would be

relatively larger given the same h_e^2. The comparison of CV R^2 and training R^2 for Naïve and

SR-TWAS approaches (Supplementary Figures 1-2) also showed that SR-TWAS outperformed

the Naïve approach under all scenarios. Because the averaging step used to obtain Avg-valid+SR

models does not include training and cross validation steps, no training R^2 or CV R^2 are

obtained for comparison.

In order to assess TWAS power, phenotypes were simulated with a certain proportion of

variance due to simulated gene expression (h_p^2). We considered a series of h_p^2 values in the range

of $(0.05, 0.875)$. The TWAS power comparison with three base models of the training and

validation data (PrediXcan-GTEx, TIGAR-ROSMAP, and TIGAR-ROSMAP_valid), Naïve

method, SR-TWAS, and Avg-valid+SR models were shown in **Fig. 2**, where the results were

consistent with the test R^2 comparison as in **Fig. 1**. The Avg-valid+SR approach performed best,

followed by SR-TWAS, TIGAR-ROSMAP training base models, and TIGAR-ROSMAP_valid

validation base models, while the Naïve method and the PrediXcan_GTEx training base models

performed poorly in comparison. In the $p_{\text{causal}} = 0.01$ and $h_e^2 = 0.5$ scenario, SR-TWAS slightly

outperformed Avg-valid+SR and had a noticeable advantage over the TIGAR-ROSMAP training

base models and TIGAR-ROSMAP_valid validation models. The results showed the SR-TWAS

approach indeed gained power by leveraging base models trained with multiple reference panels

and by multiple statistical methods.

Although desirable TWAS power ~80% was only obtained in simulation scenarios with a

relatively high h_p^2 that might be higher than the value in real studies, simulation power would

increase along with increased test sample sizes. Because real GWAS test data would have a

larger sample size than the 800 considered in our simulations, we expect desirable power for our

SR-TWAS method in real studies.

Additional simulation studies

Additionally, we conducted similar simulation studies for two other settings, where samples from

ROS/MAP and GTEx cohorts have the same set of true causal SNPs (i.e., the same genetic

architecture), and (i) the expression heritability was the same for both ROS/MAP and GTEx V8

cohorts, or (ii) the expression heritability for GTEx V8 cohort was half that of the ROS/MAP

cohort. The results of these settings were similar to that of the previously described setting. Avg-

valid+SR still had the best performance, while SR-TWAS, TIGAR-ROSMAP training base

models, and TIGAR-ROSMAP_valid validation base models outperformed the PrediXcan-GTEx

training base models and Naïve models.

Comparisons of CV R^2 and training R^2 for Naïve and SR-TWAS approaches for these scenarios

(Supplementary Figures 3, 4, 7, and 8) showed that SR-TWAS outperformed the Naïve approach

under all scenarios. For all considered scenarios, again the highest test R^2 was obtained under a

sparse causality model with high expression heritability (Supplementary Figures 5 and 9). Power

comparison results show that the Avg-valid+SR models obtained the highest power in most

scenarios, while SR-TWAS, TIGAR-ROSMAP training base models, and TIGAR-

ROSMAP_valid validation base models generally outperformed the PrediXcan-GTEx training

base models and the Naïve models (Supplementary Figures 6 and 10). The SR-TWAS approach

gained more power in the setting in which the expression heritability for GTEx V8 cohort was

only half that of ROS/MAP (Supplementary Figure 10). SR-TWAS once again had the best

performance in the $p_{\text{causal}} = 0.01$ and $h_e^2 = 0.5$ scenario under both of these additional settings.

 Model weights estimated by SR-TWAS

Plots of the weights (zeta values) of base models that were estimated by SR-TWAS in all three

simulation settings and 12 scenarios (Supplementary Figure 11) showed that the SR-TWAS

training consistently estimated higher weights for the TIGAR-ROSMAP training base models

compared to the PrediXcan-GTEx training base models, with many models selecting only the

TIGAR-ROSMAP training base model (ie, models in which the zeta value estimate for the

TIGAR-ROSMAP training base model is 1 and the zeta value estimate for the PrediXcan-GTEx

model is 0). This makes sense because the validation data were generated under the same model

assumptions as the ROSMAP training data. In particular, when the GTEx training data were also

generated under the same model as the validation data (orange bars in Supplemental Figure 11),

zeta value estimates for the TIGAR-ROSMAP models are more evenly distributed in [0, 1] for

scenarios with sparse causality model (p_causal = 0.001) and high expression heritability (he2 =

0.2, 0.5). When the GTEx training data were generated under a different setting where half of the

true causal eQTL in the validation data were also causal in the ROSMAP training data (black

bars in Supplemental Figure 11), the zeta value for the TIGAR-ROSMAP base model is more

frequently estimated to be 1.

Even when both ROSMAP and GTEx training data were generated under the same model

assumptions, the SR-TWAS method is still shown with gained power because the two base

models trained by TIGAR and PrediXcan have complementary properties. In particular,

PrediXcan uses a parametric penalized regression model with Elastic-Net penalty which is

preferred for sparse genetic architecture of gene expression quantitative traits. Whereas TIGAR

uses a nonparametric Bayesian Dirichlet process regression model which assumes an

infinitesimal model for the underlying genetic architecture of gene expression quantitative traits.

As shown in previous studies[9], PrediXcan will perform better when the true causal eQTL is

sparse, while TIGAR will perform better as the true causal eQTL proportion increases. Our

simulation studies showed that SR-TWAS had improved performance across various scenarios

with (p_{causal}= 0.001, 0.01, 0.05, 0.1; $h_e^2 = 0.1, 0.2, 0.5$; Supplementary Figure 5).

Type I error assessment

We also assessed type I error under the example scenario with $p_{causal} = 0.1$, $h_e^2 = 0.1$. Base

model weights for TIGAR-ROSMAP, PrediXcan-GTEx, and TIGAR-ROSMAP-valid were

permuted 10^6 times. The TIGAR-ROSMAP and PrediXcan-GTEx training base models with

permuted weights were then used to obtain SR-TWAS and Naïve models. The Avg-valid+SR

was obtained by averaging the SR-TWAS models and TIGAR-ROSMAP_valid training base

models with permuted weights. All models were then used to conduct gene-based association

tests with a phenotype generated randomly from $N(0, 1)$. As shown in Supplementary Table 2,

all models controlled well for type I errors for significance thresholds ($10^{-4}, 10^{-5}, 2.5 \times$

$10^{-6}, 10^{-6}$).

Real Validation Studies

To compare the GReX prediction accuracy with real gene expression data, we considered three

sets of base models that were trained by TIGAR with ROS samples (n=237,

TIGAR_ROS_DLPFC) of dorsolateral prefrontal cortex (DLPFC) tissue, trained by TIGAR with

GTEx V8 data of brain frontal cortex tissue (n=157, TIGAR_GTEx_BRNCTXB)[9], and trained

by PrediXcan with the same GTEx reference data of brain frontal cortex tissue (n=157,

PrediXcan_GTEx_BRNCTXB)[7,8,17]. SR-TWAS (SR-TWAS_MAP_DLPFC) and Naïve

(Naive_MAP_DLPFC) models were trained from these three sets of base models with respect to

a validation dataset with half of the MAP samples (n=114, randomly selected) of DLPFC tissue.

Valid gene expression imputation models trained by SR-TWAS and Naïve methods with 5-fold

CV $R^2 > 0.5\%$ in validation data were tested using the other half of the MAP samples (n=114)

of DLPFC tissue.

By comparing test R^2 obtained by SR-TWAS, Naïve, and three sets of base models in the test

MAP samples (Supplementary Table 3), we showed that PrediXcan_GTEx_BRNCTXB[7,8,17] had

the highest median (0.070) and mean (0.113) test R^2 but only for 867 valid gene expression

imputation models, SR-TWAS had the second highest median (0.026) and mean (0.068) test R^2

for 8425 valid genes expression imputation models, and Naïve model performed similarly to SR-

TWAS but with a slightly lower median (0.025) and mean (0.065) test R^2 and fewer valid genes

expression imputation models (8360). By pair-wise comparison of test R^2 for all genes with

valid expression imputation models (Supplementary Figure 12), SR-TWAS (y-axis) performed

noticeably better than the Naïve and three sets of base models (x-axis).

Application TWAS of AD Dementia

Training expression imputation models of SMA tissue by SR-TWAS

We considered four sets of base models — TIGAR and PrediXcan models trained with 465

ROS/MAP samples of DLPFC tissue (TIGAR_ROSMAP_DLPFC,

PrediXcan_ROSMAP_DLPFC), TIGAR and PrediXcan models trained with 157 GTEx V8

samples of prefrontal cortex tissue (TIGAR_GTEx_BRNCTXB[9], PrediXcan_GTEx_BRNCTXB

[7,8,17]). An additional 76 ROS/MAP samples of the supplementary motor area (SMA) brain tissue

were used as the validation dataset to train SR-TWAS models and to calculate the 5-fold CV R^2

that was used to select genes with valid imputation models. Plots of zeta weights estimated by

SR-TWAS for each set of training base models were presented in Supplementary Figure 13. We

observed that the weights of the TIGAR_GTEx_BRNCTXB[9] training base models was estimated

to be 1 more often than the other training base models. These results showed that the base

models trained by TIGAR with the GTEx data of BRNCTXB tissue

(TIGAR_GTEx_BRNCTXB[9]) contributed solely to SR-TWAS models for almost half of the

genes, which was consistent with the numbers of valid gene expression imputation models as

shown in Table 1.

PrediXcan and TIGAR models trained using the 76 ROS/MAP samples of SMA validation

dataset (PrediXcan_ROSMAP_SMA, TIGAR_ROSMAP_SMA) were also included for

comparison and were averaged with SR-TWAS models to obtain an additional set of models

(Avg-valid+SR). Here, we compared Avg-valid+SR and SR-TWAS models to training base

models, as well as validation base models trained by PrediXcan and TIGAR using the validation

data of the target SMA brain tissue, to show the advantages of SR-TWAS for leveraging multiple

regression models, multiple reference panels, and multiple tissues.

By comparing the CV R^2 and numbers of genes with valid expression imputation models (**Table**

1), we found that gene expression imputation models trained by SR-TWAS for the SMA tissue

(SR-TWAS_ROSMAP_SMA) had the highest median CV R^2 (0.072) and second highest mean

CV R^2 (0.09) for ~20K genes with valid expression imputation models. Although the

PrediXcan_GTEx_BRNCTXB[7,8,17] training base models had the third highest median CV R^2

(0.061) and highest mean CV R^2 (0.10), only 4563 genes had valid expression imputation

models. These results showed that SR-TWAS obtained improved CV R^2 in a real validation

cohort of SMA tissue by leveraging multiple regression methods from two reference panels of

multiple relevant tissues.

TWAS results of AD dementia

By using the eQTL weights obtained by training base models, validation base models, SR-

TWAS models, and Avg-valid+SR models, we conducted TWAS with the summary-level data

of the recent GWAS of AD dementia (n=~762K)[18]. Since Avg-valid+SR models were shown to

have the best performance in our simulation studies, here we focused on summarizing the results

by Avg-valid+SR here. In particular, Avg-valid+SR identified a total of 89 significant TWAS

risk genes of AD dementia with p-values $< 2.5 \times 10^{-6}$. Of these, 19 are known GWAS risk

genes, 70 are within 1Mb of a known GWAS risk gene, and 14 have been previously observed as

TWAS risk genes of AD dementia[19–24] (Supplementary Table 4).

Validation of Significant TWAS Risk Genes of AD by PMR-Egger

In order to account for potential horizontal pleiotropy effects (genetic effects on phenotype that

are not mediated by the considered GReX), we applied the PMR-Egger tool to the 89 significant

TWAS risk genes of AD obtained by the Avg-valid+SR models. This analysis was performed

using the same validation transcriptomic dataset and GWAS summary data as in the application

TWAS of AD dementia. Of these 89 analyzed genes, 61 (68.5%) had a significant causal p-value

by PMR-Egger after Bonferroni correction for multiple testing.

Independent significant TWAS risk genes of AD dementia

Because TWAS considers genotype data within a $\pm$1Mb region of the test gene, nearby

significant TWAS genes with overlapping test regions often have correlated GReX values and

might not represent independent associations. We curated 6 independent TWAS risk genes of

AD from the 61 significant genes that were validated by PMR-Egger (**Table 2, Fig. 3**) by

selecting the most significant gene in a cluster of significant genes with overlapped test regions

as the independent risk gene. We found that 1 of these independent risk genes, *HLA-DRA,* was a

known GWAS[21,25] risk gene and also previously observed as a TWAS risk gene[20]. The other 5

independent risk genes were near known GWAS risk genes[18,20,21,25–27] and near previously

observed TWAS risk genes[19,21]. Compared to the TWAS results using training base models

(Supplementary Figure 14) and validation base models (**Fig. 3**), Avg-valid+SR models identified

the greatest number of independent risk genes.

Application TWAS of PD

Training expression imputation models of brain substantia nigra tissue by SR-TWAS

We considered six sets of base models trained by TIGAR on six different tissues from GTEx V8

— brain anterior cingulate cortex BA24 (BRNACC) (n=136), brain caudate basal ganglia

(BRNCDT) (n=173), brain cortex (BRNCTXA) (n=184), brain nucleus accumbens basal ganglia

(BRNNCC) (n=182), brain putamen basal ganglia (BRNPTM) (n=154), and whole blood

(BLOOD) (n=574). With these six sets of training base models, an additional 101 GTEx samples

of brain substantia nigra (BRNSNG) tissue were used as the validation data to train SR-TWAS

models. We presented the plots of zeta weights of training base models that were estimated by

SR-TWAS in Supplementary Figure 15. For all 6 sets of considered training base models, zeta

weights were similarly distributed with 0's for most genes and other values distributed over (0,

1). 5-fold CV R^2s were calculated and used to select genes with valid expression imputation

models for TWAS. PrediXcan and TIGAR models trained on the validation data of brain

substantia nigra tissue (PrediXcan_GTEx_BRNSNG[7,8,17], TIGAR_GTEx_BRNSNG[9]) were used

to obtain average models (Avg-valid+SR) of these two sets of validation base models and SR-

TWAS models.

By comparing the CV R^2 and number of genes with valid expression imputation models (**Table**

3), we found that gene expression imputation models trained by SR-TWAS for the brain

substantia nigra tissue (SR-TWAS_GTEx-BRNSNG[9]) had the highest median CV R^2 (0.068)

and highest mean CV R^2 (0.094) for ~23K genes with valid expression imputation models.

These results showed that SR-TWAS obtained improved CV R^2 in a real validation cohort of

substantia nigra tissue by leveraging multiple regression methods from two reference panels of

multiple relevant tissues.

TWAS results of PD

We conducted TWAS using GWAS summary statistics by the recent GWAS of PD (n=~33K

cases, ~18k UK Biobank proxi-cases, and ~828K controls)[28], using eQTL weights estimated by

the above 6 sets of training base models of multiple tissues, validation base models of the

BRNSNG tissue, SR-TWAS models, and Avg-valid+SR models (Supplementary Figure 16).

Here, we also focused on the results by using the Avg-valid+SR models (**Fig. 4; Table 4;**

Supplementary Table 5), including a total of 60 significant TWAS risk genes of PD. Of these,

11 are known GWAS risk genes, 47 are within 1Mb of a known GWAS risk gene, and 11 have

been previously observed as TWAS risk genes of PD.

Validation of Significant TWAS Risk Genes of PD by PMR-Egger

We applied the PMR-Egger tool to the 60 significant TWAS risk genes of PD obtained by the

Avg-valid+SR models. This analysis was performed using the same validation transcriptomic

dataset and GWAS summary data as in the application TWAS of PD. Of these genes, 46 (76.6%)

had a significant causal p-value by PMR-Egger after Bonferroni correction for multiple testing.

Independent Significant PD TWAS Risk Genes

Similarly, from these 46 replicated risk genes with significant causal p-values by PMR-Egger,

we curated 9 independent TWAS risk genes of PD (**Fig. 4; Table 4**), including 6 novel TWAS

risk genes (*LA16c-431H6.7*, *ADORA2B*, *AC005082.12*, *MAPK8IP1P2*, *MYLPF*, and *PARL*). Of

these novel TWAS risk genes, four (*AC005082.12*, *MAPK8IP1P2*, *MYLPF*, and *PARL*) are near

known GWAS risk genes (*GPNMB*[28,29], *MAPT*[28] , *MCCC1*[28], *SETD1A*[28], *ZSWIM7*[30]). The other

3 previously observed TWAS risk genes were also known GWAS risk genes (*CD38*[29,30],

MMRN1[28,30], and *NDUFAF2*[28]). Compared to the TWAS results using these six training base

models (Supplementary Figure 16) and validation base models (**Fig. 4**), Avg-valid+SR models

still identified the greatest number of independent risk genes that were validated by PMR-Egger.

Discussion

We present a novel TWAS tool (SR-TWAS) using the ensemble machine learning technique of

stacked regression[14,15,31] for leveraging multiple gene expression imputation models (i.e., base

models) trained by different regression methods and/or using different transcriptomic reference

panels of different tissue types. We also constructed a set of average models (Avg-valid+SR) of

the SR-TWAS models and validation base models that were trained using the validation data.

Different from existing methods such as UTMOST[12] and SWAM[13], SR-TWAS requires only

summary-level base models, providing the flexibility of using publicly available base models.

With comprehensive simulation studies, we compared the Avg-valid+SR models to SR-TWAS

models, the naïve approach of averaging all training base models, training base models, and

validation base models. We showed that the Avg-valid+SR expression imputation models had

the best prediction accuracy and led to the best TWAS power across 11 out of 12 considered

scenarios, and that SR-TWAS models performed the best in the remaining scenario.

In the real data validation and application studies using ROS/MAP and GTEx V8 reference

panels and GWAS summary data of Alzheimer's disease (AD) dementia and Parkinson's disease

(PD), Avg-valid+SR models also outperformed base models trained using single reference panels

and tissue types. Avg-valid+SR models identified a greater number of total independent risk

genes that were replicated by PMR-Egger than any of the base training or validation models.

Besides known GWAS/TWAS risk genes that were identified by Avg-valid+SR models, we also

found 5 novel independent TWAS risk genes for AD dementia and 6 novel independent TWAS

risk genes for PD with known functions in respective disease pathology (Table 2; Table 4). Most

of these novel findings are located within 1Mb region of previously known GWAS and TWAS

risk genes. Additionally, we found interesting biological interpretations relevant to AD dementia

and PD for our identified TWAS risk genes.

Important findings by application TWAS of AD dementia

The results of the TWAS of AD include genes with known associations with AD dementia, or

with relevant biological processes like immune response and regulation of AD-associated genes.

Among these 6 curated independent significant genes by Avg-valid+SR models (**Table 2**), *HLA-*

DRA is located in the major histocompatibility complex region that is expressed in glial cells[32]

and which has also been previously identified by eQTL analysis[21]. The other 5 independent

significant TWAS AD risk genes of AD (*AC092849.1*, *AL110118.2*, *FOSB*, *RN7SL225P*, and

SRD5A3P1) are within 1Mb of known GWAS risk genes of AD[18,20,21,25–27] and previously

observed TWAS risk genes[19,20]. *FOSB* was the most significant of a cluster of 38 identified

significant TWAS risk genes with test region overlapped with the well-known GWAS risk gene

APOE[18,20,21,27,33,34] (**Fig. 3**). An alternatively-spliced product of the *FOSB* gene has been

implicated in the regulation of gene expression and cognitive dysfunction in mouse models of

AD[35]. *SRD5A3P* is located in the AD-associated *MS4A* gene cluster[26], which contains multiple

known GWAS risk genes[18,20–22] as well as TWAS risk gene *MS4A2*[19] of AD. The *MS4A* gene

cluster is notable due its role in the regulation of soluble TREM2, which is encoded by the

known AD risk gene *TREM2*, in cerebrospinal fluid in AD[26].

Important findings by application TWAS of PD

Similarly, results of the TWAS of PD include genes with known associations with PD, with

related conditions, and with relevant biological processes like inflammation. Among these 9

curated independent significant genes (**Table 4**), *PARL* plays a role in regulating cellular

processing of the mitochondrial kinase protein encoded by *PINK1*, mutations in which are a

known cause recessively-inherited, early-onset PD[36]. *NDUFAF2* encodes for a component of

mitochondrial complex I and loss of its functionality results in a rare mitochondrial

encephalopathy with frequent substantia nigra pathology and motor symptoms[37]. *NDUFAF2* was

also identified as a potential drug target in a Mendelian randomization study of potential drug

targets for PD treatment[38]. A study of PD-associated *GPNMB* found that it is upregulated with

lncRNA gene *AC005082.12*[39].

Additionally, *ADORA2B* encodes adenosine receptor A2B which is an important cell receptor

involved in numerous pathways and implicated in a broad variety of diseases including asthma,

sepsis, inflammatory bowel disease, cancer, renal disease, diabetes, vascular diseases, and lung

disease[40,41]. The immunomodulatory effects and role in inflammatory processes have made A2B

a target for pharmacological therapeutics[40]and antagonists the similar adenosine receptor A2A

were the first non-dopaminergic drug therapy for PD[42]. *MAPK8IP1P2* is a pseudogene near a

known TWAS PD risk gene *LRRC37A2*[30] (also identified by Avg-valid+SR models). *CD38* is

involved in neurodegeneration, neuroinflammation, and aging[30,43]. *MMRN1* is a carrier protein

for platelet factor V and lies ~84KB downstream of a well-established GWAS PD risk locus

found in multiple populations[28].

Tool for implementing SR-TWAS

The SR-TWAS tool, including options for constructing SR-TWAS models, models by the Naïve

method, and Avg-valid+SR models, is publicly-available on GitHub. The SR-TWAS tool

implements user-friendly features, including accepting genotype data in standard VCF-format as

input, enabling parallel computation, and using efficient computation strategies to reduce time

and memory usage. The most computationally expensive part is to train all base models with

different reference panels, which is subject to the regression method. For example, with training

sample size n=465, PrediXcan (Elastic-Net) costs ~1 CPU minute and TIGAR (DPR) costs ~3

CPU minutes on average per gene. Publicly-available trained models can also be used as base

models by the SR-TWAS tool. The process of training SR-TWAS models from base models and

validation data is quite computational efficient. For example, with the ROS/MAP SMA tissue

validation dataset (n=76) and four base models in our real studies SR-TWAS model training

costs ~15 CPU seconds per gene. With the GTEx substantia nigra tissue validation dataset

(n=101) and six base models in our real studies SR-TWAS model training costs ~103 CPU

seconds per gene.

Limitations

SR-TWAS still has its limitations. For example, SR-TWAS only considers cis-eQTL during

model training, uses the standard two-stage TWAS, requires an additional validation dataset of

the target tissue independent of those used for base model training[15], and assumes samples of the

reference panels and validation dataset are of the same ancestry[44].

First, previous studies have illustrated the importance of considering both cis- and trans- eQTL

in TWAS[45], and a joint modeling of the gene expression imputation and the gene-based

association test[46] [47]. The stacked regression technique used by SR-TWAS also applies to

scenarios considering both cis- and trans- eQTL, when base models trained with both cis- and

trans- eQTL are available.

Second, because the standard two-stage TWAS was implemented by SR-TWAS, the potential

horizontal pleiotropy (i.e., genetic effects on the phenotype of interest that are not mediated by

GReX) was not considered. However, the recently published PMR-Egger[48] tool that tests the

genetic effects mediated through the GReX term while controlling for horizontal pleiotropy

could be used to validate the findings by SR-TWAS.

Third, in this study we only evaluated scenarios where reference samples used to train base

models are of the same ancestry as the validation data. Although the method can be generalized

to scenarios where base and validation data are of different ancestries, having at least one set of

training base models with the same ancestry as the validation data would be a requirement for

promising TWAS results. Evaluating the performance of SR-TWAS with base models of

multiple ancestries is beyond the scope of this study, and is part of our ongoing study.

Summary

Overall, the SR-TWAS tool provides a useful resource for researchers to take advantages of the

publicly-available gene expression imputation models by using multiple regression methods

(e.g., PrediXcan[7,8], FUSION[16], TIGAR[9]) and different reference panels of multiple tissue types

(e.g., ROS/MAP[11], GTEx V8[10]). In particular, the final trained gene expression imputation model

by SR-TWAS will be with respect to the same tissue type as the validation data set. Because

multiple base models would not only increase the robustness of the gene expression imputation

model but also increase the total effective training sample size, SR-TWAS is expected to further

increase TWAS power for studying complex human diseases. The approach of constructing

average models of the SR-TWAS models and validation base models (Avg-valid+SR) provides a

set of optimal gene expression imputation models that can leverage both training base models

and validation base models to achieve the best TWAS performance.

Acknowledgements

RP and JY are supported by National Institutes of Health (NIH/NIGMS) grant award

R35GM138313. MPE was supported by NIH/NIGMS grant award R01GM117946 and NIH/NIA

grant award RF1AG071170. ROS/MAP study data were provided by the Rush Alzheimer's

Disease Center, Rush University Medical Center, Chicago, IL. Data collection was supported

through funding by NIA grants P30AG10161, R01AG15819, R01AG17917, R01AG30146,

R01AG36836, R01AG56352, U01AG32984, U01AG46152, U01AG61356, the Illinois

Department of Public Health, and the Translational Genomics Research Institute.

Table 1. Comparison of CV R^2 of SMA tissue for valid gene expression imputation models trained by training base models with ROS/MAP and GTEx V8 reference panels of DLPFC tissue, validation base models, SR-TWAS models, and Avg-valid+SR models.

	Sample Size	Median CV R^2	Mean CV R^2	N_{genes}
PrediXcan_GTEx_BRNCTXB[7,8,17a]	157	0.061	0.101	4563
PrediXcan_ROSMAP_DLPFC[a]	465	-	-	6532
TIGAR_GTEx_BRNCTXB[9a]	157	0.038	0.065	21921
TIGAR_ROSMAP_DLPFC[a]	465	0.017	0.049	11981
PrediXcan_ROSMAP_SMA[b]	76	0.031	0.053	23888
TIGAR_ROSMAP_SMA	76	0.064	0.077	32350
SR-TWAS_ROSMAP_SMA	-	0.072	0.090	20216
Avg-valid+SR	-	-	-	32238

a. Base training model used by SR-TWAS;
b. Base validation model.

Table 2. Independent TWAS risk genes of AD dementia identified by Avg-valid+SR models of SMA tissue. TWAS Zscores and p-values were presented here for the models of Avg-valid+SR, SR-TWAS, PrediXcan validation base models, and TIGAR validation base models. The signs of Zscores show the directions of the mediated genetic effects on AD dementia.

		Avg-valid+SR ROSMAP SMA		SR-TWAS ROSMAP SMA		PrediXcan ROSMAP SMA		TIGAR ROSMAP SMA	
Gene	CHR	Zscore	P-value	Zscore	P-value	Zscore	P-value	Zscore	P-value
HLA-DRA[ac]	6	-6.81	1.00e-11	-6.88	5.93e-12	-	-	-	-
AC092849.1[bd]	7	6.54	6.23e-11	-	-	6.48	9.02e-11	5.98	2.21e-09
SRD5A3P1[bd]	11	8.73	2.49e-18	-	-	-	-	8.73	2.49e-18
RN7SL225P[bd]	11	5.05	4.33e-07	-	-	5.03	5.02e-07	4.93	8.04e-07
AL110118.2[bd]	14	-5.32	1.01e-07	-	-	-5.25	1.52e-07	-5.63	1.77e-08
FOSB[bd]	19	29.19	2.44e-187	-	-	29.20	1.87e-187	13.79	2.98e-43

a. Known GWAS risk gene of AD.
b. Gene within 1Mb of known GWAS risk gene of AD.
c. Previously observed TWAS risk gene of AD.
d. Gene within 1Mb of previously observed TWAS risk gene of AD.

Table 3. Comparison of CV R^2 of BRNSNG tissue for valid gene expression imputation models trained by training base models with GTEx V8 reference panel of multiple tissues, validation base models, SR-TWAS models, and Avg-valid+SR models.

	Sample Size	Median CV R^2	Mean CV R^2	N_{genes}
TIGAR_GTEx_BRNACC[9a]	136	0.040	0.062	23068
TIGAR_GTEx_BRNCDT[9a]	173	0.034	0.063	23362
TIGAR_GTEx_BRNCTXA[9a]	184	0.033	0.066	23379
TIGAR_GTEx_BRNNCC[9a]	182	0.033	0.060	23382
TIGAR_GTEx_BRNPTM[9a]	154	0.037	0.062	22481
TIGAR_GTEx_BLOOD[9a]	574	0.020	0.071	16682
TIGAR_GTEx_BRNSNG[9b]	101	0.050	0.068	23051
PrediXcan_GTEx_BRNSNG[7,8,17b]	101	0.052	0.080	2559
SR-TWAS_GTEx_BRNSNG	-	0.068	0.094	22913
Avg-valid+SR	-	-	-	21683

a. Base training model used by SR-TWAS;
b. Base validation model.

Table 4. Independent TWAS risk genes of Parkinson's disease identified by Avg-valid+SR models of SMA tissue. TWAS Zscores and p-values were presented here for the models of Avg-valid+SR, SR-TWAS, PrediXcan validation base models, and TIGAR validation base models. The signs of Zscores show the directions of the mediated genetic effects on AD dementia.

Gene	CHR	Avg-valid+SR GTEx BRNSNG		SR-TWAS GTEx BRNSNG		PrediXcan GTEx BRNSNG		TIGAR GTEx BRNSNG	
		Zscore	P-value	Zscore	P-value	Zscore	P-value	Zscore	P-value
PARL[bd]	3	-4.75	2.02e-06	-	-	-	-	-	-
CD38[ac]	4	7.59	3.31e-14	7.68	1.57e-14	-	-	-	-
MMRN1[ac]	4	-7.99	1.34e-15	-7.91	2.55e-15	-7.90	2.80e-15	-8.50	1.95e-17
NDUFAF2[ac]	5	-5.33	9.80e-08	-5.45	4.91e-08	-	-	-	-
AC005082.12[bd]	7	5.94	2.83e-09	5.47	4.44e-08	-	-	5.35	8.66e-08
LA16c-431H6.7	16	-4.95	7.60e-07	-	-	-	-	-	-
MYLPF[bd]	16	6.34	2.31e-10	-	-	-	-	6.31	2.78e-10
ADORA2B[d]	17	-5.02	5.16e-07	-5.20	2.04e-07	-4.94	7.96e-07	-5.29	1.21e-07
MAPK8IP1P2[bd]	17	9.31	1.30e-20	9.05	1.39e-19	-	-	9.42	4.38e-21

a. Known GWAS risk gene of PD.
b. Gene within 1Mb of known GWAS risk gene of PD.
c. Previously observed TWAS risk gene of PD.
d. Gene within 1Mb of previously observed TWAS risk gene of PD.

Figures legends

Fig. 1. Boxplots of gene expression prediction R^2 for simulations with varying proportion of true causal SNPs $p_{\text{causal}} = (0.001, 0.01, 0.05, 0.1)$ and true expression heritability $h_e^2 = (0.1, 0.2, 0.5)$. Avg-valid+SR models obtained the highest test R^2 for gene expression imputation across all 11 of 12 scenarios, while SR-TWAS performed best in the scenario with $p_{\text{causal}} = 0.01$ and $h_e^2 = 0.5$. This is because test samples are simulated under the same genetic architecture as the ROSMAP training cohort and the validation cohort, which only have ~50% overlapped true causal SNPs as the GTEx training cohort.

Fig. 2. Power comparison for simulations with varying proportion of true causal SNPs $p_{\text{causal}} = (0.001, 0.01, 0.05, 0.1)$**, true expression heritability** $h_e^2 = (0.1, 0.2, 0.5)$**, and phenotype heritability** $h_p^2 \in (0.05, 0.875)$**.** Similar patterns were observed as shown in Fig. 1, where Avg-valid+SR models obtained the highest test R^2 for gene expression imputation across all 11 of 12 scenarios and SR-TWAS models performed best in the scenario with $p_{\text{causal}} = 0.01$ and $h_e^2 = 0.5$.

Fig. 3. Manhattan plots of TWAS results by validation base models, SR-TWAS models, and Avg-valid+SR models of SMA tissue for studying AD dementia. Validation base models were trained by PrediXcan and TIGAR using the ROS/MAP validation data of SMA tissue. Avg-valid+SR models were obtained by averaging the SR-TWAS and these two sets of validation base models. A total of 89 (6 independent and significantly causal by PMR-Egger) TWAS risk genes were identified by the Avg-valid+SR models. Significant genes are shown in orange and significant genes discussed in the main text are labeled and shown in red.

Fig. 4. Manhattan plots of TWAS results by validation base models, SR-TWAS models, and Avg-valid+SR models of substantia nigra tissue for studying Parkinson's Disease. Validation base models were trained by PrediXcan and TIGAR using the GTEx validation data of substantia nigra tissue. Avg-valid+SR models were obtained by averaging the SR-TWAS and these two sets of validation base models. A total of 60 (9 independent and significantly causal by PMR-Egger) significant TWAS risk genes were identified by the Avg-valid+SR models. Significant genes are shown in orange and significant genes discussed in the text are labeled and shown in red.

Methods

SR-TWAS using Stacked Regression

Stacked regression is a machine learning method for forming optimal linear combinations of

different predictors to improve prediction accuracy[15]. The theoretical background for combining

predictors rather than selecting a single best predictor is well-established and has been developed

since the 1970s[15,49,50]. The "stacking" method of combining predictors originated in a 1992

paper[14] by Wolpert, who described the concept as any scheme for feeding information from a set

of cross-validated models to another before forming the final prediction in order to reduce

prediction error[14]. The idea is further expanded with stacked regression, a specific framework for

combining the initial predictors by weighted average with coefficient constraints to control for

multicolinearity[15].

In standard two-stage TWAS, we need to first fit a gene expression imputation model, which is

assumed as a multivariable linear regression model, with quantitative gene expression levels E_g

for the target gene and tissue type as the response variable, and genotype matrix G of

nearby/genome-wide SNPs as predictors,

598
$$E_g = Gw + \epsilon, \qquad \epsilon_i \sim N(0, 1).$$

This gene expression imputation model can be trained per gene per tissue type, using a

transcriptomic reference panel which profiles both transcriptomic and genetic data of the same

training cohort. SNPs with non-zero effect sizes w are referred to as a broad sense of eQTL. The

eQTL effect sizes w will be estimated from each trained model by different regression methods

and/or using different reference data of multiple tissue types.

Assume there are a total of K base gene expression imputation models that are trained for the

same target gene and tissue type, with $\widehat{w_k}, k = 1, \ldots, K$, as the trained eQTL effect sizes per base

model. Let $\mathbf{E}_{vg}$ denote the gene expression levels of the same target gene g and tissue type in the

validation data, and $\mathbf{G}_v$ denote the genotype matrix of the same genetic predictors in the

validation data. Then the predicted Genetically Regulated gene eXpression (GReX) of the

validation samples are given by $\mathbf{G}_v \widehat{\mathbf{w}}_k$, by the kth base model. The stacked regression

method[14,15] will solve for a set of optimal model weights $\zeta_1, \ldots, \zeta_K$, by maximizing the regression

R^2 between the profiled gene expression $\mathbf{E}_{vg}$ and the weighted average GReX, $\sum_{k=1}^{K} \zeta_k \, \mathbf{G}_v \widehat{\mathbf{w}}_k$, of

K base models, ie, minimizing the following loss function of $1 - R^2$:

$$\text{minimize}_{(\zeta_k; \, k=1,\ldots,K)} \frac{\left\| \mathbf{E}_{vg} - \sum_{k=1}^{K} \zeta_k \, \mathbf{G}_v \widehat{\mathbf{w}}_k \right\|^2}{\left\| \mathbf{E}_{vg} - \bar{E}_{vg} \right\|^2}, \qquad \text{s.t.} \sum_{k=1}^{K} \zeta_k = 1, \quad \zeta_k \in [0,1].$$

As a result, we will obtain a set of model weights ζ_k for $k = 1, \ldots, K$ base models, and a set of

eQTL effect sizes $\widetilde{\mathbf{w}}$ given by the weighted average of the eQTL effect sizes of K base models,

$\widetilde{\mathbf{w}} = \sum_{k=1}^{K} \zeta_k \, \widehat{\mathbf{w}}_k$ (Stage I). Then the final predicted GReX for test genotype data $\mathbf{G}_t$ is given by

$\widehat{\text{GReX}}_g = \mathbf{G}_t \widetilde{\mathbf{w}}$, and $\widetilde{\mathbf{w}}$ will be taken as variant weights in the gene-based association tests by

SR-TWAS in Stage II.

Genes with 5-fold CV $R^2 > 0.5\%$ in the validation dataset by SR-TWAS are considered as

having a valid imputation model and will be tested in Stage II. That is, the validation dataset will

be randomly split into 5 folds. For each fold of data, SR-TWAS model will be trained using the

other 4-fold data and then use to calculate prediction R^2 with the current fold. The average

prediction R^2 across all 5 folds of data is considered as the 5-fold CV R^2. Here, we use a more

liberal threshold (0.005) than the threshold 0.01 used by previous studies [16,51,52] to allow more

genes to be tested in follow-up TWAS. Because the follow-up gene-based association Z-score

test statistic is essentially a weighted average of single variant GWAS Z-score statistics with

variant weights provided by the eQTL effect sizes[9], poorly estimated eQTL weights would only

reduce power but will not increase false positive rate under null hypothesis.

Naïve Method

In this paper, we compared SR-TWAS to a Naïve approach which just takes the average of base

models as the trained gene expression imputation model, that is, takes $\zeta_k = \frac{1}{K}, k = 1, ..., K$.

Using a validation dataset, we can still evaluate the validation R^2 which can be used to select

valid genes with validation $R^2 > 0.5\%$.

Avg-valid+SR Models

We further constructed average models of the SR-TWAS models and validation base models

trained using the validation dataset, which are referred to as Avg-valid+SR models. Because SR-

TWAS and validation base models are averaged directly, training R^2 and CV R^2 are not obtained

for Avg-valid+SR models. We compared the Avg-valid+SR models to the SR-TWAS models

and validation base models in both simulation and real studies.

SR-TWAS Tool Framework

SR-TWAS tool was designed to be compatible with the TIGAR-V2 tool framework[9]; it accepts

models trained by TIGAR-V2 as input, imports utility functions from TIGAR-V2, and outputs

model files which can be used as input for TIGAR-V2 GReX prediction and summary-level

TWAS. Much of the structure of the SR-TWAS code was derived from existing TIGAR-V2

scripts and it shares dependencies on TABIX[53] and the Python libraries of numpy[54,55], pandas[54],

scipy[56], statsmodels[57], and scikit-learn[58,59].

The SR-TWAS script utilizes scikit-learn's consistent, extensible interfaces for defining

estimators and predictors and for initializing objects[59]. The script trains a stacked regression

model using a modified version of scikit-learn's StackingRegressor class, which trains a final

estimator from cross-validated predictions from base estimators fitted on the full design matrix.

The script defines two custom classes to be used as input for the stacking regressor object: a base

estimator class (WeightEstimator) which converts trained GReX prediction models into scikit-

learn-compatible estimator objects and a final estimator class (ZetasEstimator) which obtains the

values of $\zeta_1, \dots, \zeta_K$ that minimize the loss function under the constraints $\zeta_k \geq 0$ and $\sum_{k=1}^{K} \zeta_k =$

1[15].

During the stacked regression, SNP minor allele frequencies and effect sizes for the specified

target are first read from each of the K user-specified weight files. The SNPs are then matched to

SNPs in the validation genotype data and filtered to exclude effect sizes of SNPs for which the

difference between the MAF of the genotype data and the MAF from the corresponding weight

file exceeds a user-specified MAF difference threshold. The effect sizes from each weight file

are used to initialize K separate instances of the WeightEstimator class. These K

WeightEstimator objects are used as base estimators and fit on genotype and expression data

from the validation data.

A separate script allows users to specify one or more base models trained on the validation data

to average with the SR-TWAS model produced in the previous step. The tool will read SNP

effect sizes for the specified target from each of these models and output an Avg-valid+SR

model averaged from the validation data base model(s) and the model obtained by stacked

regression.

Only SR-TWAS models trained from $K = 2, 4, 6$ base models are presented in this paper. The

code was designed to accept any $K \geq 2$, and while the stacked regression script has been

primarily tested using $K = 2, 4, 6$ base models, preliminary testing with dummy weight files

confirms it can train stacked regression models from $K > 6$ base models.

ROS/MAP Reference Panel

The Religious Orders Study (ROS) and Rush Memory and Aging Project (MAP) are two

ongoing longitudinal, epidemiologic clinical-pathologic cohort studies of aging and Alzheimer's

disease collectively referred to as ROS/MAP[11]. ROS enrolls Catholic nuns, priests, and brothers

from religious groups across the United States, primarily from communal living settings[11]. While

the similar adult lifestyle of participants allows for more control of potential confounders such as

education and socioeconomic status, it simultaneously limits the ability to study such variables[11].

MAP was designed to complement and extend studies like ROS by including subjects from a

wider range of life experiences, socioeconomic status, and educational attainment and recruits

participants primarily from retirement communities in the Chicago area, but also subsidized

housing, retirement homes, and through organizations serving minorities and low-income

elderly[11]. All participants in both studies are without known dementia and agree to annual

clinical evaluations and brain donation upon death[11]. Similarity in study design and data

collection procedures allows the ROS and MAP datasets to be merged for use in joint

analyses[11,60].

Quality-controlled ROS/MAP WGS data for European subjects[60] were used for both the real data

application and simulation studies. Transcriptomic data of ROS/MAP samples of brain PFC were

profiled by RNA-sequencing (RNA-seq). Gene expression data of Transcripts Per Million (TPM)

per sample were provided by Rush Alzheimer's Disease Center. Genes with > 0.1 TPM in ≥ 10

samples were considered. Raw gene expression data (TPM) were then log2 transformed and

adjusted for age at death, sex, postmortem interval, study (ROS or MAP), batch effects, RNA

integrity number scores, cell type proportions (with respect to oligodendrocytes, astrocytes,

microglia, neurons), top five genotype principal components, and top probabilistic estimation of

expression residuals (PEER) factors[61] by linear regression models. SNPs with minor allele

frequency (MAF) $> 1\%$, Hardy-Weinberg p-value $> 10^{-5}$ were analyzed. For each gene, cis-

SNPs within the 1Mb of the flanking 5' and 3' ends were used in the imputation models as

predictors.

GTEx V8 Reference Panel

The Genotype-Tissue Expression (GTEx) project V8 profiles both whole genome sequencing

(WGS) genotype data and RNA-seq transcriptomic data for Brain PFC tissue type of n=157

donors[10]. Gene expression data of Transcripts Per Million (TPM) per sample per tissue were

downloaded from the GTEx portal. Genes with > 0.1 TPM in ≥ 10 samples were considered.

Raw gene expression data (TPM) were then log2 transformed and adjusted for age, body mass

index (BMI), top five genotype principal components, and top probabilistic estimation of

expression residuals (PEER) factors[61]. SNPs with minor allele frequency (MAF) $> 1\%$, Hardy-

Weinberg p-value $> 10^{-5}$ were analyzed. For each gene, cis- SNPs within the 1Mb of the

flanking 5' and 3' ends were used in the imputation models as predictors.

Simulation Study Design

We conducted in depth simulation studies under various scenarios to assess the performance of

SR-TWAS, Avg-valid+SR, a Naïve method, and training base models by PrediXcan and

TIGAR. We used the real genotype data of gene *ABCA7* from ROS/MAP and GTEx V8 to

simulate gene expression and phenotypes. We considered three different settings: (i) Samples

from ROS/MAP and GTEx cohorts have the same set of true causal SNPs (i.e., the same genetic

architecture). The expression heritability was the same for both ROS/MAP and GTEx V8

cohorts. (ii) Samples from ROS/MAP and GTEx cohorts have the same set of true causal SNPs

(i.e., the same genetic architecture). The expression heritability for GTEx V8 cohort is only half

of the one for ROS/MAP. (iii) Samples from the ROS/MAP cohort were simulated with the same

causal SNPs (i.e., eQTL), while samples from the GTEx V8 cohort were simulated with true

causal SNPs that were 50% overlapped with the ones for ROS/MAP. The expression heritability

was the same for both ROS/MAP and GTEx V8 cohorts.

Under each setting, we considered multiple scenarios with varying proportions of causal SNPs

($p_{causal} = (0.001, 0.01, 0.05, 0.1)$) and gene expression heritability (i.e., the proportion of gene

expression variation due to genetics, $h_e^2 = (0.1, 0.2, 0.5)$). We randomly selected n=465 training

samples with WGS genotype data from ROS/MAP and GTEx V8, respectively. We randomly

selected n=400 and n=800 samples with WGS genotype data from ROS/MAP as our validation

and test cohorts, respectively. We considered a series of h_p^2 values, the proportion of phenotype

variance due to simulated gene expression, in the range of $(0.05, 0.875)$.

For each scenario, gene expression $\mathbf{E}_i$ for the ith simulation iteration is generated using the

following formula

$$\mathbf{E}_i = \gamma_i \mathbf{G}^* \boldsymbol{\beta}_i + \boldsymbol{\varepsilon}_i, \qquad \gamma_i = \sqrt{\frac{h_e^2}{\text{Var}(\mathbf{G}^* \boldsymbol{\beta}_{\bullet i})}}, \qquad \boldsymbol{\varepsilon}_i \sim \text{N}\left(0, \sqrt{1 - h_e^2}\right),$$

where $\mathbf{G}^*$ denotes the genotype matrix of N_{causal} randomly chosen true causal SNPs for all

samples, effect size vector $\boldsymbol{\beta}_i$ was generated from $N(0, I)$, and γ_i is a scale factor chosen to

ensure the targeted h_e^2 value. The phenotype vector $\mathbf{Y}_i$ for the ith simulation iteration was

generated using the following formula

744
$$\mathbf{Y}_i = \varphi_i \mathbf{E}_i + \boldsymbol{\varepsilon}_i, \qquad \varphi_i = \sqrt{\frac{h_p^2}{\text{Var}(\mathbf{E}_i)}}, \qquad \boldsymbol{\varepsilon}_i \sim \mathrm{N}\left(0, \sqrt{1 - h_p^2}\right)$$

where $\mathbf{E}_i$ is the simulated gene expression, and φ_i is a scale factor to ensure the targeted h_p^2

value.

Two base models per gene were trained by PrediXcan with the GTEx training samples (n=465)

(PrediXcan-GTEx), and by TIGAR with the ROS/MAP training samples (n=465) (TIGAR-

ROSMAP). SR-TWAS and Naïve models were then obtained by using these trained base

models. Validation data ($n = 400$) were used to train SR-TWAS models and filter out gene

expression imputation models with 5-fold cross-validation $R^2 < 0.5\%$ in the validation cohort

for both SR-TWAS and Naïve models. A validation data base model was trained by TIGAR on

the validation data (TIGAR-ROSMAP_valid) to compare results with that of the ensemble

models and to obtain a model from the average of the the validation data base models and SR-

TWAS (Avg-valid+SR). Test data (n=800) were used for assessing GReX prediction

performance and TWAS power. Each causal simulation scenario was repeated for 1,000 times.

We compared the performance by SR-TWAS, Avg-valid+SR, the Naïve method, training base

models, and validation base models with respect to prediction imputation R^2 in the test data and

the power of TWASs.

The predicted $\widehat{\text{GReX}}_i$ by each trained gene expression imputation model was used to calculate

expression prediction R^2, which is equivalent to the regression R^2 between profiled and

predicted gene expression, given by

$$R_{E_i}^2 = \text{Cor}\left(\mathbf{E}_i, \widehat{\text{GReX}}_i\right)^2.$$

The power will be given by the proportion of simulation iterations that have TWAS p-value $<$

2.5×10^6 out of a total of 1,000 simulation iterations.

Data availability

All ROS/MAP data analyzed in this study are de-identified and available to any qualified

investigator with application through the Rush Alzheimer's Disease Center Research Resource

Sharing Hub, https://www.radc.rush.edu, which has descriptions of the studies and available

data. GTEx V8 data are available from dbGaP with accession phs000424.v8.p2. TIGAR base

models trained from GTEx V8 are available at Synapse

https://www.synapse.org/TIGAR_V2_Resource_GTExV8. PrediXcan base models trained from

GTEx V8 are available from https://predictdb.org/. GWAS summary data of AD are available

from https://ctg.cncr.nl/software/summary_statistics, and GWAS summary data of PD are

available from https://bit.ly/2ofzGrk. TIGAR and PrediXcan base models, Avg-valid+SR, SR-

TWAS, and Naïve models trained from ROS/MAP brain PFC tissue in this study, SR-TWAS

and Avg-valid+SR models trained from GTEx brain substantia nigra tissue in this study, and all

TWAS summary statistics will be made available at SYNAPSE when the manuscript is accepted

for publication.

Code availability

The SR-TWAS tool, including the Naïve and Avg-valid+SR methods, is publicly-available on

GitHub, https://github.com/yanglab-emory/SR-TWAS. Code for replicating analyses described

in this paper is available at https://github.com/rndparr/SR-TWAS_analysis.

References

1. Feng, H. *et al.* Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. *Genet. Epidemiol.* **44**, 442–468 (2020).

2. Kar, S. *et al.* Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies new candidate susceptibility genes for breast and ovarian cancer. *bioRxiv* (2020) doi:10.1101/2020.04.23.043653.

3. Strunz, T., Lauwen, S., Kiel, C., Hollander, A. den & Weber, B. H. F. A transcriptome-wide association study based on 27 tissues identifies 106 genes potentially relevant for disease pathology in age-related macular degeneration. *Scientific Reports* **10**, 1584 (2020).

4. Wu, C. *et al.* Transcriptome-wide association study identifies susceptibility genes for rheumatoid arthritis. *Arthritis Res Ther* **23**, (2021).

5. Wainberg, M. *et al.* Opportunities and challenges for transcriptome-wide association studies. *Nat Genet* **51**, 592–599 (2019).

6. Nagpal, S. *et al.* TIGAR: An Improved Bayesian Tool for Transcriptomic Data Imputation Enhances Gene Mapping of Complex Traits. *The American Journal of Human Genetics* **105**, 258–266 (2019).

7. Barbeira, A. N. *et al.* Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics. *Nat Commun* **9**, 1–20 (2018).

8. Gamazon, E. R. *et al.* A gene-based association method for mapping traits using reference transcriptome data. *Nat Genet* **47**, 1091–1098 (2015).

9. Parrish, R. L., Gibson, G. C., Epstein, M. P. & Yang, J. TIGAR-V2: Efficient TWAS tool with nonparametric Bayesian eQTL weights of 49 tissue types from GTEx V8. *Human Genetics and Genomics Advances* **3**, 100068 (2022).

810   10.   GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human

811   tissues. *Science* **369**, 1318–1330 (2020).

812   11.   Bennett, D. A. *et al.* Religious Orders Study and Rush Memory and Aging Project. *J*

813   *Alzheimers Dis* **64**, S161–S189 (2018).

814   12.   Hu, Y. *et al.* A statistical framework for cross-tissue transcriptome-wide association

815   analysis. *Nat Genet* **51**, 568–576 (2019).

816   13.   Liu, A. E. & Kang, H. M. Meta-imputation of transcriptome from genotypes across multiple

817   datasets by leveraging publicly available summary-level data. *PLOS Genetics* **18**, e1009571

818   (2022).

819   14.   Wolpert, D. H. Stacked generalization. *Neural Networks* **5**, 241–259 (1992).

820   15.   Breiman, L. Stacked regressions. *Mach Learn* **24**, 49–64 (1996).

821   16.   Gusev, A. *et al.* Integrative approaches for large-scale transcriptome-wide association

822   studies. *Nature Genetics* **48**, 245–252 (2016).

823   17.   Barbeira, A. N. *et al.* Exploiting the GTEx resources to decipher the mechanisms at GWAS

824   loci. *Genome Biology* **22**, 49 (2021).

825   18.   Wightman, D. P. *et al.* A genome-wide association study with 1,126,563 individuals

826   identifies new risk loci for Alzheimer's disease. *Nat Genet* **53**, 1276–1282 (2021).

827   19.   Mancuso, N. *et al.* Integrating Gene Expression with Summary Association Statistics to

828   Identify Genes Associated with 30 Complex Traits. *The American Journal of Human*

829   *Genetics* **100**, 473–487 (2017).

830   20.   Marioni, R. E. *et al.* GWAS on family history of Alzheimer's disease. *Transl Psychiatry* **8**,

831   99 (2018).

21. Jansen, I. E. *et al.* Genome-wide meta-analysis identifies new loci and functional pathways

influencing Alzheimer's disease risk. *Nat Genet* **51**, 404–413 (2019).

22. Nazarian, A., Yashin, A. I. & Kulminski, A. M. Genome-wide analysis of genetic

predisposition to Alzheimer's disease and related sex disparities. *Alz Res Therapy* **11**, 1–21

(2019).

23. Gockley, J. *et al.* Multi-tissue neocortical transcriptome-wide association study implicates 8

genes across 6 genomic loci in Alzheimer's disease. *Genome Medicine* **13**, 76 (2021).

24. Jing, Q. *et al.* A Comprehensive Analysis Identified Hub Genes and Associated Drugs in

Alzheimer's Disease. *BioMed Research International* **2021**, e8893553 (2021).

25. Schwartzentruber, J. *et al.* Genome-wide meta-analysis, fine-mapping, and integrative

prioritization implicate new Alzheimer's disease risk genes. *Nat Genet* **53**, 392–402 (2021).

26. Deming, Y. *et al.* The MS4A gene cluster is a key modulator of soluble TREM2 and

Alzheimer's disease risk. *Science Translational Medicine* **11**, eaau2291 (2019).

27. Shigemizu, D. *et al.* Ethnic and trans-ethnic genome-wide association studies identify new

loci influencing Japanese Alzheimer's disease risk. *Transl Psychiatry* **11**, 1–10 (2021).

28. Nalls, M. A. *et al.* Identification of novel risk loci, causal insights, and heritable risk for

Parkinson's disease: a meta-analysis of genome-wide association studies. *The Lancet*

Neurology **18**, 1091–1102 (2019).

29. Kia, D. A. *et al.* Identification of Candidate Parkinson Disease Genes by Integrating

Genome-Wide Association Study, Expression, and Epigenetic Data Sets. *JAMA Neurology*

78, 464–472 (2021).

30. Yao, S. *et al.* A transcriptome-wide association study identifies susceptibility genes for

Parkinson's disease. *npj Parkinsons Dis.* **7**, 1–8 (2021).

31. Sagi, O. & Rokach, L. Ensemble learning: A survey. *WIREs Data Mining and Knowledge*

Discovery **8**, e1249 (2018).

32. Tang, H. & Harte, M. Investigating Markers of the NLRP3 Inflammasome Pathway in

Alzheimer's Disease: A Human Post-Mortem Study. *Genes (Basel)* **12**, 1753 (2021).

33. Lambert, J.-C. *et al.* Genome-wide association study identifies variants at CLU and CR1

associated with Alzheimer's disease. *Nat Genet* **41**, 1094–1099 (2009).

34. Kunkle, B. W. *et al.* Genetic meta-analysis of diagnosed Alzheimer's disease identifies new

risk loci and implicates Aβ, tau, immunity and lipid processing. *Nat Genet* **51**, 414–430

(2019).

35. Corbett, B. F. *et al.* ΔFosB regulates gene expression and cognitive dysfunction in a mouse

model of Alzheimer's disease. *Cell Rep* **20**, 344–355 (2017).

36. Shi, G. *et al.* Functional alteration of PARL contributes to mitochondrial dysregulation in

Parkinson's disease. *Human Molecular Genetics* **20**, 1966–1974 (2011).

37. Subrahmanian, N. & LaVoie, M. J. Is there a special relationship between complex I

activity and nigral neuronal loss in Parkinson's disease? A critical reappraisal. *Brain*

Research **1767**, 147434 (2021).

38. Storm, C. S. *et al.* Finding genetically-supported drug targets for Parkinson's disease using

Mendelian randomization of the druggable genome. *Nat Commun* **12**, 7342 (2021).

39. Murthy, M. N. *et al.* Increased brain expression of GPNMB is associated with genome wide

significant risk for Parkinson's disease on chromosome 7p15.3. *Neurogenetics* **18**, 121–133

(2017).

40. Haskó, G., Linden, J., Cronstein, B. & Pacher, P. Adenosine receptors: therapeutic aspects

for inflammatory and immune diseases. *Nat Rev Drug Discov* **7**, 759–770 (2008).

41. Sun, Y. & Huang, P. Adenosine A2B Receptor: From Cell Biology to Human Diseases.

Frontiers in Chemistry **4**, (2016).

42. Jenner, P. Chapter Three - An Overview of Adenosine A2A Receptor Antagonists in

Parkinson's Disease. in *International Review of Neurobiology* (ed. Mori, A.) vol. 119 71–

86 (Academic Press, 2014).

43. Guerreiro, S., Privat, A.-L., Bressac, L. & Toulorge, D. CD38 in Neurodegeneration and

Neuroinflammation. *Cells* **9**, 471 (2020).

44. Mogil, L. S. *et al.* Genetic architecture of gene expression traits across diverse populations.

PLOS Genetics **14**, e1007586 (2018).

45. Luningham, J. M. *et al.* Bayesian Genome-wide TWAS Method to Leverage both cis- and

trans-eQTL Information through Summary Statistics. *The American Journal of Human*

Genetics **107**, 714–726 (2020).

46. Yang, C. *et al.* CoMM: a collaborative mixed model to dissecting genetic contributions to

complex traits by leveraging regulatory information. *Bioinformatics* **35**, 1644–1652 (2019).

47. Yuan, Z. *et al.* Testing and controlling for horizontal pleiotropy with probabilistic

Mendelian randomization in transcriptome-wide association studies. *Nature*

Communications **11**, 3861 (2020).

48. Yuan, Z. *et al.* Testing and controlling for horizontal pleiotropy with probabilistic

Mendelian randomization in transcriptome-wide association studies. *Nat Commun* **11**, 3861

(2020).

49. Rao, J. N. K. & Subrahmaniam, K. Combining Independent Estimators and Estimation in

Linear Regression with Unequal Variances. *Biometrics* **27**, 971–990 (1971).

50.   Efron, B. & Morris, C. Combining Possibly Related Estimation Problems. *Journal of the*

901   *Royal Statistical Society* **35**, 379–421 (1973).

902   51.   Wu, L. *et al.* A transcriptome-wide association study of 229,000 women identifies new

903   candidate susceptibility genes for breast cancer. *Nat Genet* **50**, 968–978 (2018).

904   52.   Bhattacharya, A., Li, Y. & Love, M. I. MOSTWAS: Multi-Omic Strategies for

905   Transcriptome-Wide Association Studies. *PLoS Genet* **17**, e1009398 (2021).

906   53.   Li, H. Tabix: fast retrieval of sequence features from generic TAB-delimited files.

907   *Bioinformatics* **27**, 718–719 (2011).

908   54.   McKinney, W. Data Structures for Statistical Computing in Python. in *Proceedings of the*

909   *9th Python in Science Conference (SciPy 2010)* 56–61 (2010). doi:10.25080/Majora-

910   92bf1922-00a.

911   55.   Harris, C. R. *et al.* Array programming with NumPy. *Nature* **585**, 357–362 (2020).

912   56.   Virtanen, P. *et al.* SciPy 1.0: fundamental algorithms for scientific computing in Python.

913   *Nature Methods* **17**, 261–272 (2020).

914   57.   Seabold, S. & Perktold, J. Statsmodels: Econometric and Statistical Modeling with Python.

915   in *Proceedings of the 9th Python in Science Conference (SciPy 2010)* 92–96 (2010).

916   doi:10.25080/Majora-92bf1922-011.

917   58.   Pedregosa, F. *et al.* Scikit-learn: Machine learning in python. *Journal of Machine Learning*

918   *Research* **12**, 2825–2830 (2011).

919   59.   Buitinck, L. *et al.* API design for machine learning software: experiences from the scikit-

920   learn project. in *Proceedings of the European Conference on Machine Learning and*

921   *Principles and Practices of Knowledge Discovery in Databases (ECMPKDD'13)* 108--122

922   (2013).

923   60. De Jager, P. L. *et al.* A multi-omic atlas of the human frontal cortex for aging and

924   Alzheimer's disease research. *Sci Data* **5**, (2018).

925   61. Stegle, O., Parts, L., Piipari, M., Winn, J. & Durbin, R. Using probabilistic estimation of

926   expression residuals (PEER) to obtain increased power and interpretability of gene

927   expression analyses. *Nat Protoc* **7**, 500–507 (2012).